Coherus Biosciences Inc.
CHRS
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 ( PD-1 ) inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma ( NPC ) and advance t…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$54M
▲ +59.8% YoY
Net Income (TTM)
-$136M
▲ +489.4% YoY
Op. Margin
-275.94%
▲ +327.1pp YoY
ROIC
-200.43%
▲ +2120.6pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$609M
▼ -145.2% YoY
Op. Cash Flow (TTM)
-$174M
▼ -577.7% YoY
Net Debt
-$82M
Net Cash Position
Cash & Equiv.
$84M
5Y CAGR: -38.4%
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CHRS
Held by ETFs
CHRS is in 4 US ETFs. The largest of them, with CHRS's weight in each:
Coherus Biosciences (CHRS) in four numbers
Questions about Coherus Biosciences
Is Coherus Biosciences (CHRS) overvalued?
At $0.53, Coherus Biosciences' price is 16% below the $0.62 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Coherus Biosciences' fair value?
Intrinsiqq's calculator puts Coherus Biosciences' fair value at $0.62 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 2.9, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.47. Every input can be changed on the Intrinsic Value tab.
Is Coherus Biosciences a high-quality business?
Coherus Biosciences scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$82M, and its weakest is return on capital at -200.4%. The Quality tab shows every check against its target.
Does Coherus Biosciences (CHRS) pay a dividend?
No. Coherus Biosciences (CHRS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 31 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 13 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CHRS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CHRS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.